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OPEN
ORIGINAL ARTICLE
RNF168 cooperates with RNF8 to mediate FOXM1
ubiquitination and degradation in breast cancer epirubicin
treatment
M Kongsema1,5, S Zona1,5, U Karunarathna1,5, E Cabrera2, EPS Man3, S Yao1, A Shibakawa1, U-S Khoo3, RH Medema4, R Freire2
and EW-F Lam1
The forkhead box M1 (FOXM1) transcription factor has a central role in genotoxic agent response in breast cancer. FOXM1 is
regulated at the post-translational level upon DNA damage, but the key mechanism involved remained enigmatic. RNF168 is a
ubiquitination E3-ligase involved in DNA damage response. Western blot and gene promoter-reporter analyses showed that the
expression level and transcriptional activity of FOXM1 reduced upon RNF168 overexpression and increased with RNF168 depletion
by siRNA, suggesting that RNF168 negatively regulates FOXM1 expression. Co-immunoprecipitation studies in MCF-7 cells revealed
that RNF168 interacted with FOXM1 and that upon epirubicin treatment FOXM1 downregulation was associated with an increase in
RNF168 binding and conjugation to the protein degradation-associated K48-linked polyubiquitin chains. Consistently, RNF168
overexpression resulted in an increase in turnover of FOXM1 in MCF-7 cells treated with the protein synthesis inhibitor
cycloheximide. Conversely, RNF168, knockdown signiﬁcantly enhanced the half-life of FOXM1 in both absence and presence of
epirubicin. Using a SUMOylation-defective FOXM1-5x(K4R) mutant, we demonstrated that SUMOylation is required for the
recruitment of RNF168 to mediate FOXM1 degradation. In addition, clonogenic assays also showed that RNF168 mediates
epirubicin action through targeting FOXM1, as RNF168 could synergise with epirubicin to repress clonal formation in wild-type but
not in FOXM1-deﬁcient mouse embryo ﬁbroblasts (MEFs). The physiological relevance of RNF168-mediated FOXM1 repression is
further emphasized by the signiﬁcant inverse correlation between FOXM1 and RNF168 expression in breast cancer patient samples.
Moreover, we also obtained evidence that RNF8 recruits RNF168 to FOXM1 upon epirubicin treatment and cooperates with RNF168
to catalyse FOXM1 ubiquitination and degradation. Collectively, these data suggest that RNF168 cooperates with RNF8 to mediate
the ubiquitination and degradation of SUMOylated FOXM1 in breast cancer genotoxic response.
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INTRODUCTION
Breast cancer is one of the leading causes of death in women
worldwide. Anthracyclines, platinum compounds, methylating
agents and ionizing irradiation are common genotoxic anticancer
agents employed for the treatment of breast cancer patients not
suitable for endocrine therapy as well as those with secondary or
metastatic diseases. Moreover, these DNA-damaging agents are
used after primary treatments, such as surgery or radiation, to
prevent cancer recurrence. However, patients invariably develop
resistance to these genotoxic agents, resulting in ineffective
treatment, cancer progression and disease relapse.1 The insur-
gence of genotoxic agent resistance is primarily mediated through
cellular DNA damage response (DDR). DDR involves the initiation
of DNA damage repair, the activation of cell-cycle checkpoint and
the induction of apoptosis or senescence, which ultimately
inﬂuence sensitivity to genotoxic chemotherapy and cell fate.
The Forkhead box M1 (FOXM1) transcription factor has a pivotal
role in promoting cell proliferation, migration, invasion, angiogen-
esis, stem cell renewal and DNA damage repair, thus inﬂuencing
cancer initiation, progression, metastasis, angiogenesis and drug
sensitivity. Recent research also indicates that deregulated FOXM1
overexpression confers genotoxic and other cancer chemother-
apeutic agent resistance.2–7 There is already ample evidence,
indicating that FOXM1 acts as a mediator of DDR and a modulator
of genotoxic agent sensitivity, through regulating the expression
of genes, including BRIP1, NBS1, EXO1, XRCC1, RAD51 and RFC4,
involved in DDR.4,5,8–10 Despite the importance of FOXM1 in
DNA-damaging agent response, the exact mechanisms by which
FOXM1 is regulated by genotoxic agents remain a crucial
unresolved issue.
Ubiquitination is a post-translational modiﬁcation whereby
ubiquitins (Ubs) become covalently conjugated to target proteins.
This process has a key role in regulating cellular protein stability,
activity, interaction and localization. Ubiquitination is a three-step
enzymatic process, involving ubiquitin activation, conjugation and
ligation, mediated by ubiquitin-activating enzymes (E1s),
ubiquitin-conjugating enzymes (E2s) and ubiquitin ligases (E3s),
respectively. The E3-ubiquitin ligases recognize the speciﬁc target
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proteins to be ubiquitinated and therefore also dictate substrate
speciﬁcity.11 K(Lys)48- and K(Lys)63-linked polyubiquitination
polymers are the predominantly ubiquitin chains found on cellular
proteins. While proteins with K48-linked ubiquitin polymers are
commonly targeted for degradation by the proteasome,
K63-linked ubiquitin chains are usually associated with other
protein regulatory functions, such as modulating the activity,
function and subcellular location of the target proteins or altering
protein–protein interactions.
Epirubicin is an anthracycline commonly used for the treatment
of breast cancer.12 Upon epirubicin treatment, FOXM1 is primarily
downregulated at the post-translational level in breast cancer
cells.8,13,14 In line with this, we have recently shown that in
response to epirubicin treatment, FOXM1 is modiﬁed through
SUMOylation, which leads to its ubiquitination and degradation
via the proteasome proteolytic pathway.15 A novel subgroup of
E3-ligases called SUMO-targeted Ubiquitin E3-ligases (STUbLs)
provide a link for cross-talks between the SUMO and ubiquitin
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pathways. Of these STUbLs, a subset, including RNF4 and -8, has
been shown to have a speciﬁc role in double-strand break (DSB)
DDR.11,16–19 Our proteomic analysis has also identiﬁed another
related DDR Ubiquitin E3-ligase RNF168 as a putative
FOXM1-interacting protein. These ubiquitin E3-ligases are found
primarily in the nucleus and their known DDR functions are also
identiﬁed in the nucleus.20 On the basis of these observations,
we speculated that these ubiquitin E3-ligases may modulate
FOXM1 expression in breast cancer cells and in response to the
genotoxic agent epirubicin. To establish a connection between
Figure 1. RNF168 negatively regulates FOXM1 expression and cell proliferation in MCF-7 cells. (a) Western blot analysis was performed on
MCF-7 cells transfected with empty expression vector (pcDNA3) and Flag-RNF4, HA-RNF8 or Flag-RNF168 expression vector for 48 h. The
protein expression levels of FOXM1, the RNF E3-ligase and β-tubulin were assessed by western blot analysis (asterisk indicates the non-speciﬁc
protein band). FOXM1 expression was observed to be downregulated by RNF168, but not by RNF4 and RNF8, at the protein level. (b) MCF-7
cells were transfected with NSC siRNA, or with RNF4, RNF8 or RNF168 speciﬁc siRNA pool for 48 h. The protein expression levels of FOXM1, the
RNF E3-ligase and β-tubulin were assessed by western blot analysis. FOXM1 expression was observed to be upregulated by the silencing of
RNF168, but not RNF4 and RNF8, at the protein level. (c) MCF-7 cells were either untransfected (Mock), or transfected with pcDNA3-empty
vector, with RNF168 or with Flag-RNF168 for 48 h. Western blot analysis was performed on the transfected MCF-7 cells with or without 1 μM
epirubicin treatment for 24 h. The protein expression levels of FOXM1, RNF168, Flag-(RNF168) and β-tubulin were assessed by western blot
analysis. (d) MCF-7 cells were transfected with NSC siRNA, siRNA pool targeting RNF168, pcDNA3-empty vector or pcDNA3-Flag-RNF168.
Twenty-four hours after transfection, aliquots of the transfected cells were split into 96-well plates with concentrations of epirubicin indicated
and their proliferation analysed at 48 h by SRB assays. Cell proliferation assays revealed that Flag-RNF168 overexpression increased and
RNF168 depletion with siRNA decreased epirubicin sensitivity in MCF-7 cells. The results presented as bars representing mean± s.d. of three
independent experiments in triplicates. The differences between that RNF168 overexpression or depletion and their relative controls are
signiﬁcant at *Po0.05 levels, except for those untreated.
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Figure 2. Overexpression of RNF168, but not RNF4 and RNF8, effectively repressed FOXM1 transcriptional activity. (a) Schematic showing of the WT
(pGL2-Cyclin B1-WT) and the FOXM1-mutant (pGL2-Cyclin B1-mut) Cyclin B1 promoter/reporter. (b) MCF-7 cells were co-transfected with the WT cyclin
B1 promoter (pGL2-Cyclin B1-WT) and 20 ng of the empty expression vector (pcDNA3), Flag-RNF4, HA-RNF8 or Flag-RNF168 expression vector. Forty-
eight hours after transfection, the transfected cells were western blotted for the expression of FOXM1, RNF168, RBF8, RNF4 and β-tubulin. (c) MCF-7
cells were co-transfected with the luciferase reporter driven by the WT cyclin B1 promoter (pGL2-Cyclin B1-WT) and the empty expression vector
(pcDNA3) or the Flag-RNF4, HA-RNF8 or Flag-RNF168 expression vector (0–50 ng) for 48 h as in (b). Reporter gene activity was expressed as a ratio of
ﬁreﬂy luciferase activity to control Renilla luciferase activity. The promoter activity assay results are presented as bars representing mean± s.d. of three
independent experiments in triplicates. All DNA concentrations were normalized using empty vector. (d) MCF-7 cells were co-transfected with Flag-
RNF168 expression vector (0, 5, 10, 20, 30 and 50 ng) and the luciferase reporter driven by the WT cyclin B1 promoter (pGL2-Cyclin B1-WT) or the
mutant cyclin B1 promoter (pGL2-Cyclin B1-mut) and the Flag-RNF168 expression vector (0–50 ng) for 48 h. Reporter gene activity was expressed as a
ratio of ﬁreﬂy luciferase activity to control Renilla luciferase activity. The promoter activity assay results are presented as bars representing mean± s.d.
of three independent experiments in triplicates. **P⩽0.01, ***P⩽0.001 and ns indicates no signiﬁcance by Student's t-test.
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epirubicin-induced FOXM1 SUMOylation and its subsequent
targeting to the proteasome for degradation, we sought to
identify the ubiquitin E3-ligase(s) involved. We established in this
study the ubiquitin E3-ligases RNF8 and RNF168 as the down-
stream effectors that collectively recognize and mediate the
functional consequences of FOXM1 SUMOylation in response to
epirubicin treatment.
RESULTS
RNF168 downregulates FOXM1 expression in MCF-7 breast cancer
cells
Our previous proteomic study identiﬁed the E3-Ubiquitin
ligase RNF168 as a potential FOXM1-interacting protein.
Given the role of RNF168 as an E3-Ubiquitin ligase and the
involvement of ubiquitination in the epirubicin-induced FOXM1
downregulation,14,15 we hypothesized that RNF168 binds FOXM1
and modulates its expression through the ubiquitin-proteasome
degradation pathway. To explore this possibility, we ﬁrst over-
expressed RNF168 and two other DDR-related E3-ligases, RNF4
and RNF8, in the MCF-7 breast carcinoma cells, and studied their
effects on FOXM1 expression (Figure 1a). We found that while
RNF168 decreased and RNF4 increased FOXM1 expression, RNF8
expression had little effect on the expression levels of FOXM1.
Conversely, depletion of RNF4 using siRNA repressed FOXM1
expression, whereas RNF168 knockdown induced FOXM1 accu-
mulation in MCF-7 cells (Figure 1b). Once again, RNF8 silencing
had little effect on FOXM1 expression in untreated MCF-7 cells.
Together, these data suggest that RNF168, and not RNF4, is a key
negative regulator of FOXM1 expression in untreated MCF-7 cells.
To conﬁrm this further, we overexpressed either an untagged or a
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Figure 3. FOXM1 complexes with RNF168 in MCF-7 cells. (a) MCF-7 cells co-transfected with either the empty expression vectors,
pcDNA3-HA and pcDNA3-Flag, or Flag-RNF168 and HA-FOXM1 were treated with epirubicin (1 μM) for 0, 6 and 24 h.
Co-immunoprecipitation (co-IP) was performed with an FOXM1 (αFOXM1) antibody on lysates from these transfected MCF-7 cells
pretreated with 10 M MG132; Inputs (1/10 of IP) and IP products with αFOXM1 were resolved on western blot and probed for FOXM1,
HA-(FOXM1) and RNF168 expression. Notably, treatment with the proteasome inhibitor MG132 produced high levels of smearing in the
western blots, which are undegraded or semi-degraded ubiquitinated protein species. (b) Co-immunoprecipitation was performed on
MCF-7 cells treated with epirubicin (1 μM) for 0, 6 and 24 h. IP was performed with IgG and an RNF168 (αRNF168) antibody on lysates from
these transfected MCF-7 cells. IP products with IgG and a RNF168 antibody (αRNF168) were resolved on western blot and probed for
RNF168 and FOXM1. FOXM1* represents a FOXM1 species associated with its SUMOylation.15 (c) MCF-7 cells were treated with epirubicin
(1 μM) for 0, 6 and 24 h. Co-IP was performed with IgG and a FOXM1 antibody (αFOXM1); Inputs (1/10 of IP) and IP products with IgG and a
FOXM1 antibody (αFOXM1) were resolved on western blot and probed for RNF168 and FOXM1.
RNF168 and RNF8 promote FOXM1 degradation
M Kongsema et al
4
Oncogenesis (2016), 1 – 16
Flag-tagged RNF168 in MCF-7 cells (Figure 1c). Consistently, the
results showed that overexpression of RNF168 effectively down-
regulated FOXM1 in the absence and presence of epirubicin
treatment. These results suggest that RNF168 can downregulate
FOXM1 expression and might mediate the anti-proliferative effects
of epirubicin. To test this idea, we overexpressed and depleted
RNF168 in MCF-7 cells and assessed their proliferation in response
to different doses of epirubicin. In agreement, the results indicated
that RNF168 silencing decreased the anti-proliferative function of
epirubicin, while RNF168 overexpression sensitized MCF-7 cells
towards epirubicin (Figure 1d).
RNF168 represses FOXM1 activity in MCF-7 breast cancer cells
To further conﬁrm our results, we next investigated the effects of
overexpression of RNF4, RNF8 and RNF168 on FOXM1 activity
using the FOXM1-regulated cyclin B1 promoter as a reporter.
Consistent with our previous overexpression and depletion data,
the promoter transactivation results showed that RNF4 increased
and RNF168 decreased signiﬁcantly the activity of the cyclin B1
reporter. In line with previous results, RNF8 expression did not
have a substantial effect on the activity of the cyclin B1 promoter
in cycling MCF-7 cells. This ability of RNF168 to speciﬁcally repress
FOXM1 activity is conﬁrmed by the observation that RNF168
repressed the activity of the wild type (WT), but not a cyclin B1,
promoter with the mutated FOXM1-binding site (Figure 2b). These
results further veriﬁed a role for RNF168 in repressing FOXM1
expression and activity.
RNF168 interacts with FOXM1 in breast cancer cells
To explore the mechanism by which RNF168 represses FOXM1
expression, we next overexpressed Flag-RNF168 and HA-FOXM1 in
MCF-7 cells treated with epirubicin for 0, 6 and 24 h, and studied
the interaction of these ectopically expressed proteins by
co-immunoprecipitation. The results showed that RNF168
interacted with FOXM1, suggesting that FOXM1 and RNF168 form
complexes in breast cancer cells both in the absence and in the
presence of epirubicin (Figure 3a). To further conﬁrm this, we
carried out co-immunoprecipitation studies on the endogenous
RNF168 and FOXM1 protein in MCF-7 cells treated with epirubicin
for 0, 6 and 24 h. Consistently, the results showed that RNF168
co-immunoprecipitated with FOXM1 and vice versa, afﬁrming that
RNF168 interacts with FOXM1 (Figure 3b).
Epirubicin induces the association of RNF168 and K48
polyubiquitin chains with FOXM1
Given that RNF168 is an E3-Ubiquitin ligase involved in DDR, we
proposed that RNF168 binds FOXM1 upon epirubicin treatment and
mediates its downregulation through the ubiquitin-proteasome
degradation pathway. To test this conjecture, we examined whether
RNF168 binding is associated with the induction of FOXM1
ubiquitination in response to epirubicin treatment and studied by
co-immunoprecipitation the levels of RNF168, RNF8 and the
degradation-related K48-linked polyubiquitin chains associated with
FOXM1 in the presence of the proteasome inhibitor MG132 in
epirubicin-treated MCF-7 cells (Figure 4). The results revealed that the
FOXM1-associated RNF168 protein and K48 ubiquitination chains
were at low levels in untreated MCF-7 cells. However, epirubicin
treatment caused a signiﬁcant increase in RNF168 protein and K48
ubiquitination chains co-precipitated with FOXM1 following 6 and
24 h of epirubicin. Conversely, the amounts of FOXM1 and FOXM1
bound RNF8 were at high levels in untreated cells and increased
transiently at 6 h before decreasing at 24 h. Quantiﬁcation of the
relative levels of K48-linked polyubiquitin chains, RNF168, and RNF8
associated with FOXM1, revealed that the relative levels of K48-linked
polyubiquitin chains and RNF168 associated with FOXM1 actually
increased over time upon epirubicin treatment, while the levels of
RNF8 bound to FOXM1 increased marginally at 6 h before declining
upon epirubicin treatment. Notably, the increase in RNF168 and K48
ubiquitination chains associated with FOXM1 followed similar kinetics
and coincided with the decrease in FOXM1 expression, consistent
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Figure 4. The downregulation of FOXM1 expression by epirubicin is associated with an increase in RNF168 binding and an increase in Lys48-
linked polyubiquitin conjugates in MCF-7 cells. (a) Protein lysates prepared from MCF-7 and cells at 0, 6 and 24 h following treatment with
1 μM epirubicin were subjected to immunoprecipitation with a FOXM1 antibody (αFOXM1). The input and immunoprecipitates were then
analysed by western blot analysis using antibodies against K48-linked ubiquitin, K63-linked ubiquitin, RNF168, RNF8 and FOXM1.
Representative co-immunprecipitation results are shown. (b) The K48-linked polyubiquitin, K63-linked polyubiquitin, RNF168, RNF8 and
FOXM1 images were quantiﬁed using ImageJ analysis and plotted against signals at 0 h. The ratios of K48-Ub- and K63-Ub-conjugated FOXM1
relative to FOXM1 precipitates as well as FOXM1 bound RNF168 and RNF8 relative to FOXM1 precipitates were also shown. Data shown
represent the mean± s.d. from three independent experiments (t-test: 6 h or 24 h versus 0 h epirubicin treatment; *signiﬁcant Po0.05, and
***very signiﬁcant Po0.001). ANOVA was also performed on these data with post hoc test.
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Figure 5. RNF168 enhances the degradation of FOXM1 in untreated and epirubicin-treated MCF-7 cells. (a) MCF-7 cells transfected with
control pcDNA3 or Flag-RNF168 were treated with CHX, and protein lysates prepared from 0 to 8 h following cyclohexamide treatment.
Protein expression levels of FOXM1, RNF168, β-tubulin and cyclin B1 in these MCF-7 lysates were examined by western blotting. (b) MCF-7
cells transfected with control NSC siRNA or Smart Pool siRNA targeting RNF168 were treated with CHX, processed and analysed as in (a).
(c) MCF-7 cells transfected with control pcDNA3 or Flag-RNF168 were treated with 1 μM epirubicin for 16 h. Protein lysates prepared from 0 to
8 h following cyclohexamide treatment were processed and analysed as in (a). (d) MCF-7 cells transfected with control NSC siRNA or Smart
Pool siRNA targeting RNF168 were treated with 1 μM epirubicin for 16 h. Protein lysates prepared from 0 to 8 h following cyclohexamide
treatment were processed and analysed as in (a). Densitometry was used to quantify the FOXM1 and β-tubulin levels from which independent
background readings were subtracted. Western blots are representative of three independent experiments. The relative expression levels
shown (right panels) are means± s.e.m. of the ratios of FOXM1 to β-tubulin levels relative to those at 0 h, *P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.001 and
ns indicates no signiﬁcance by student's t-test.
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with the notion that RNF168 mediates the ubiquitination and
degradation of FOXM1. Despite its expression not correlating directly
with FOXM1 ubiquitination and degradation, the fact that RNF8
complexed with FOXM1 also suggests that it may nevertheless have a
part in regulating FOXM1 expression, as RNF8 is known to function
cooperatively with RNF168 to mediate DDR.11,21–23
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RNF168 decreases FOXM1 stability in MCF-7 cells and in response
to epirubicin treatment
To establish a role for RNF168 in regulating FOXM1 protein
stability, MCF-7 cells were transfected with either control vector or
RNF168, and then treated with the translation inhibitor cyclohex-
imide (CHX) (Figure 5). The results showed that the rate of FOXM1
loss was signiﬁcantly enhanced in MCF-7 cells transfected with
RNF168 compared with cells transfected with the empty vector
control (Figure 5a). Conversely, the rates for the decline in FOXM1
levels were reduced in MCF-7 cells transfected with the smart pool
siRNA targeting RNF168 compared with the non-silencing control
(NSC) siRNA pool (Figure 5b). Notably, the turnover of FOXM1 is
signiﬁcantly but only mildly reduced in MCF-7 cells with RNF168
knockdown. However, this is consistent with our ﬁnding that
RNF168 expression is low in epirubicin-untreated proliferating
MCF-7 cells. We next studied the role of RNF168 in regulating
FOXM1 stability in response to epirubicin. Under these conditions,
RNF168 overexpression decreased and its depletion increased the
stability of FOXM1 compared with the respective controls
(Figures 5c and d). Together, these results suggest that RNF168
can modulate the turnover of FOXM1 in untreated breast cancer
cells and in response to epirubicin.
RNF168 links FOXM1 SUMOylation to its degradation
To examine the hypothesis that RNF168 might link FOXM1
SUMOylation to its ubiquitination and degradation, we
co-transfected MCF-7 cells with GFP-FOXM1 (WT) or
SUMOylation-defective GFP-FOXM1-5x(K4R) together with
RNF168, and compared the ability of RNF168 to enhance the
degradation of the WT and the SUMOylation-defective FOXM1 in
the presence or absence of epirubicin treatment (Figure 6;
Supplementary Figure S1). Compared with endogenous FOXM1
without RNF168 overexpression, overexpression of RNF168
hastened the degradation of both the transfected GFP-FOXM1
(WT) and the endogenous FOXM1. In contrast, we observed that
the turnover of the SUMOylation-defective GFP-FOXM1-5x(K4R)
was not substantially affected by RNF168 overexpression,
suggesting that FOXM1 SUMOylation is required for its targeting
by RNF168 for degradation (Figure 6; Supplementary Figure S1).
To further explore the role of RNF168 in coupling FOXM1
SUMOylation to the ubiquitination and degradation pathway,
we transfected GFP-FOXM1 (WT) or SUMOylation-defective
GFP-FOXM1-5x(K4R) together with Flag-RNF168 into MCF-7 cells,
treated with epirubicin for 0, 6 and 24 h, and studied the
interaction of these ectopically expressed proteins by
co-immunoprecipitation experiments using an anti-Flag antibody
(Figure 7a; Supplementary Figure S2). The co-immunoprecipitation
results showed that RNF168 interacted with GFP-FOXM1 (WT) but
not the SUMOylation-defective GFP-FOXM1-5x(K4R), suggesting
that SUMOylation is required for the recruitment of RNF168 to
FOXM1 to mediate its ubiquitination and degradation. To conﬁrm
this further, we studied the interaction of the endogenous RNF168
with FOXM1 in MCF-7 cells in the absence and presence
of ginkgolic acid, a botanical SUMOylation inhibitor, by
co-immunoprecipitation (Figure 7b; Supplementary Figure S2).
The results showed that RNF168 and FOXM1 interact only in the
absence of ginkgolic acid, further suggesting that FOXM1
SUMOylation is required for the recruitment of RNF168.
RNF168 promotes the direct conjugation of K48-linked
polyubiquitin chains to FOXM1
To investigate whether the polyubiquitin chains are directly
conjugated to FOXM1 and to identify the polyubiquitin chains
involved, we expressed GFP-FOXM1 in the absence or presence of
the His-tagged ubiquitin mutants Ub(K48R) and Ub(K63R) that are
defective in forming K48 and K63-linked chains, respectively
(Figure 8a). The His-tagged ubiquitinated proteins were then
puriﬁed using nickel-afﬁnity columns under denaturing conditions
in the presence of the proteasome inhibitor MG132 and
immunoblotted with an anti-FOXM1 antibody, which detected
the ubiquitin-conjugated forms of FOXM1 as smears above the
predicted GFP-FOXM1 molecular weight of 160 kDa. The results
showed that the GFP-FOXM1 was conjugated to signiﬁcantly
higher levels of Ub(K63R) than Ub(K48R) polymers, suggesting
that FOXM1 is linked primarily to K48 polyubiquitin chains, which
frequently direct the degradation of target proteins by the 26S
proteasome (Figure 8a). We next tested the ability of RNF168 to
promote the formation of polyubiquitin chains directly on FOXM1.
To this end, His-tagged Ub(WT) was overexpressed with GFP-
FOXM1 alone or with GFP-FOXM1 and Flag-RNF168 together in
293T cells, puriﬁed under denaturing conditions and probed with
an anti-FOXM1 antibody. The results showed that RNF168
overexpression can further increase the amount of ubiquitin
chains directly conjugated to FOXM1 (Figure 8b). We then
compared the ability of RNF8 and RNF168 to promote the
formation of the K48 polyubiquitin chains on FOXM1 by
overexpressing His-tagged Ub(K63R) with either HA-RNF8 or
Flag-RNF168 (Figure 8c). The results revealed that while the
amounts of pulled-down FOXM1 were comparable in control cells
and the cells overexpressing RNF8 and RNF168, the amount of His-
Ub(K63R) polyubiquitinylated FOXM1 puriﬁed was much higher in
the RNF168 overexpressing cells, suggesting that RNF168 rather
than RNF8 controls the conjugation of K48-linked polyubiquitin
chains to FOXM1 in unstimulated cells. Consistent with our earlier
ﬁndings, the pull-down results also indicated that these directly
conjugated polyubiquitin chains required FOXM1 SUMOylation as
substantially lower levels of SUMOylation-defective mutant
FOXM1 were pulled down by the His-tagged Ubiquitin, compared
with the WT FOXM1 (Figure 8d). To further conﬁrm that RNF168
promotes the conjugation of K48-linked polyubiquitin chains to
FOXM1, His-tagged FOXM1 was expressed alone or with Flag-
RNF168 in MCF-7, and puriﬁed under denaturing conditions using
nickel-afﬁnity columns in the presence of MG132 (Figure 8e). The
polyubiquitin chains covalently conjugated to His-tagged FOXM1
proteins were detected with the anti-K48-linked and anti-K63-
linked polyubiquitin chain antibodies. The results revealed that
although RNF168 overexpression downregulated FOXM1 expres-
sion, the relative levels of K48-linked polyubiquitin chains formed
on FOXM1 increased with RNF168 overexpression in both
Figure 6. SUMOylation mutant of FOXM1 is resistant to RNF168-mediated degradation. (a) Asynchronous MCF-7 cells co-transfected with
RNF168 and eGFP-FOXM-1 (WT) or eGFP-FOXM1-5X(K4R) were treated with cyclohexamide and protein lysates prepared from 0 to 8 h
following cyclohexamide treatment. Protein expression levels of endogenous FOXM1/eGFP-FOXM1, RNF168 and β-tubulin in these MCF-7
lysates were examined by western blotting. Densitometry was used to quantify the FOXM1/eGFP-FOXM1 and β-tubulin levels from which
independent background readings were subtracted. Western blots are representative of three independent experiments. The relative
expression levels shown (lower panels) are means ± s.d. of the ratios of FOXM1/eGFP-FOXM1 to β-tubulin levels relative to those at 0 h.
(b) MCF-7 cells co-transfected with eGFP-FOXM1 (WT) or eGFP-FOXM1-5X(K4R) and Flag-RNF168 were treated with 1 μM epirubicin for 16 h.
Protein lysates prepared from 0 to 8 h following cyclohexamide treatment were processed and analysed as in (a). Densitometry was used to
quantify FOXM1 levels and were normalized to β-tubulin. Western blot representative of three independent experiments (see also
Supplementary Figure S1). Statistical signiﬁcance was determined by Student’s t-test (*P⩽ 0.05, **P⩽ 0.01, ***P⩽ 0.005; n.s., non-signiﬁcant) by
comparing the densitometry of eGFP-FOXM1 at a particular time.
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Figure 7. FOXM1 SUMOylation is required for its interaction with RNF168. (a) MCF-7 cells were co-transfected with RNF168 and eGFP-FOXM-1
(WT) or eGFP-FOXM1-5X(K4R). Protein lysates prepared from MCF-7 cells at 0, 6 and 24 h following treatment with 1 μM epirubicin were
subjected to immunoprecipitation with control antibodies (IgG) or an RNF168 antibody (αRNF168). The input (1/10) and immunoprecipitates
were then analysed by western blot analysis using antibodies against FOXM1, GFP and RNF168. Representative co-immunprecipitation results
demonstrating that RNF168 only interacts with wild-type FOXM1 but not the SUMOylation mutant FOXM1 are shown. *indicates the position
of the eGFP-FOXM1 band. The consistent smear patterns observed for the co-immunoprecipitated FOXM1 might reﬂect the high degrees of
FOXM1 degradation induced by RNF168 binding. (b) MCF-7 cells were treated with either vehicle or 10 μM of the protein SUMOylation
inhibitor, ginkgolic acid for 4 h. Cells were lysed in RIPA buffer containing 50 mM N-ethylmaleimide, and the lysates immunoprecipitated with
an RNF168 antibody (left panel) or a FOXM1 antibody (right panel). The input (1/10) and immunoprecipitates were then analysed by western
blot analysis using antibodies against FOXM1 and RNF168. The results showed that ginkgolic acid treatment suppresses FOXM1 and RNF168
interaction (see also Supplementary Figure S2).
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untreated and 24 h epirubicin-treated MCF-7 cells, afﬁrming that
RNF168 promotes the conjugation of K48-linked polyubiquitin
chains on FOXM1.
RNF8 is involved in the recruitment of RNF168 and the targeting of
SUMOylated FOXM1 for degradation
Although it is evident that RNF168 binds and mediates the
ubiquitination of SUMOylated FOXM1, RNF168 possesses only a
conventional ubiquitin-interacting motif, but not a SUMO-
interacting motif capable of binding speciﬁcally to
SUMO-conjugated proteins. This evokes the involvement of a
STUbL in the initial recognition and ubiquitination of SUMOylated
FOXM1. The fact that the DNA damage-related STUbL RNF8
interacts with FOXM1 suggests it might be the STUbL that
recognizes SUMOylated FOXM1 and cooperates with RNF168 to
mediate FOXM1 ubiquitination and degradation. To test this idea,
we examined the effects of overexpression or silencing of RNF8 on
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Figure 8. FOXM1 is modiﬁed by ubiquitination and its K48-linked polyubiquitin conjugates can be induced by RNF168 and epirubicin.
(a) 293T cells were co-transfected with eGFP-FOXM1 and empty control expression vector, His-Ubiquitin(K48R) or His-Ubiquitin(K63R).
Ubiquitinated proteins were puriﬁed using Ni2+-column afﬁnity pull-down under denaturing conditions (Guanidinium Chloride). Input and
His-tagged Ubiquitin pulled-down proteins were probed for FOXM1 using an anti-FOXM1 antibody. The result showed that higher levels of
His-Ub(K63R) were conjugated to FOXM1, suggesting that FOXM1 is primarily covalently linked to K48 polyubiquitin conjugates. (b) 293T cells
were co-transfected with eGFP-FOXM1 and empty control expression vector or His-Ubiquitin and in the absence or presence of Flag-RNF168.
Ubiquitinated proteins were puriﬁed using Ni2+-column afﬁnity pull-down under denaturing conditions. The input (1/10) and pulled-down
proteins were western blotted for FOXM1 expression. The results showed that RNF168 overexpression can further enhance FOXM1
ubiquitination. (c) 293T cells were co-transfected with His-Ub(K63R) in the presence or absence of HA-RNF8 or Flag-168. Ubiquitinated
proteins were puriﬁed under denaturing conditions and probed with FOXM1. The results suggested that RNF168, but not RNF8, can induce
FOXM1-K48 polyubiquitination. (d) 293T cells were co-transfected with His-Ub and eGFP-FOXM-1 (WT) or eGFP-FOXM1-5X(K4R). His-tagged
ubiquitinated proteins were puriﬁed under denaturing conditions. The pulled-down His-Ub conjugated proteins were western blotted for
FOXM1 expression. The results showed that substantially higher levels of eGFP-FOXM1 WT proteins were pulled down with the His-Ub than
the SUMOylation-defective mutant, despite the mutant being the more stable species, suggesting that SUMOylation promotes FOXM1
ubiquitination. (e) MCF-7 cells were transfected with His-FOXM1 and Flag-RNF168 or control empty expression vector. Twenty-four hours after
transfection, the cells were lysed, the His-tagged FOXM1 puriﬁed using Ni2+-column afﬁnity pull-down under denaturing conditions and
probed with FOXM1, speciﬁc K48-linked and K63-linked polyubiquitin antibodies. The results indicated that RNF168 predominantly enhances
FOXM1-K48 polyubiquitination in untreated and epirubicin-treated MCF-7 cells.
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the expression and stability of FOXM1 in MCF-7 cells before and
after epirubicin treatment (Figure 9). Western blot analysis showed
that RNF8 overexpression and silencing decreased and increased
the expression of FOXM1 in MCF-7 cells respectively, but only in
cells after epirubicin treatment (Figure 9a). This is in agreement
with our earlier results that RNF8 overexpression or depletion has
little effect on FOXM1 expression in untreated MCF-7 cells
(Figure 1a). Consistently, we found that co-expression of RNF8
signiﬁcantly shortened the half-life of FOXM1, while silencing of
RNF8 signiﬁcantly enhanced the stability of FOXM1 following CHX,
in epirubicin-treated MCF-7 cells but not in the untreated cells
(Figure 9b; Supplementary Figure S3). To examine whether RNF8
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preferentially targets SUMOylated FOXM1 for degradation, we
compared the effects of RNF8 on the stability of WT and
SUMOylation-defective FOXM1 after CHX treatment. The result
showed that co-expression of RNF8 signiﬁcantly shortened the
half-life of WT FOXM1 but not the FOXM1-5X(K4R) mutant
following epirubicin treatment, suggesting that RNF8 targets
SUMOylated FOXM1 for degradation in response to epirubicin
treatment (Figure 10a). Our reverse co-immunoprecipitation
experiment (Figure 10b) further conﬁrmed our earlier result that
RNF8 interacts with FOXM1 (Figure 4). To further establish our
hypothesis, we next investigated whether RNF8 is required for the
interaction of RNF168 with FOXM1 (Figure 10c) The result showed
that RNF8 is required for the binding of endogenous RNF168 to
FOXM1, as depletion of RNF8 using siRNA abolished the
interaction between RNF168 and FOXM1 (Figure 10c). To assess
this possibility further, we co-expressed Flag-RNF168 with
HA-tagged FOXM1 in MCF-7 cells and performed
co-immunoprecipitation analysis (Figure 10d). The result
conﬁrmed further that RNF8 is required for the interaction
between RNF168 and FOXM1. Taken together, our data provide
strong evidence that RNF8 is recruited to the SUMOylated FOXM1
to mediate the initial FOXM1 ubiquitination, which results in the
recruitment of RNF168 to further enhance FOXM1 ubiquitination
and degradation.
RNF168 and RNF8 restrict cell proliferation and promote epirubicin
sensitivity through targeting FOXM1
FOXM1 has been shown to enhance cancer cell proliferation and
protect cells from genotoxic agents by promoting DNA damage
repair.5,8,13 Considering our ﬁnding that RNF168 and RNF8 target
FOXM1 for degradation in response to epirubicin, we next
investigated whether FOXM1 is a target for the anti-proliferative
function of RNF168 and RNF8. To this end, we transfected RNF168
and RNF8 into WT and Foxm1−/− mouse embryo ﬁbroblasts
(MEFs), and studied their effects on cell proliferation and in
response to epirubicin by clonogenic assay (Figure 11). The results
showed that overexpression of RNF168 or RNF8 repressed colony
formation and synergized with epirubicin to repress colony
formation in WT MEFs, but neither RNF168 nor RNF8 over-
expression had any signiﬁcant effects on the clonogenicity of
Foxm1−/−MEFs in response to epirubicin, suggesting FOXM1 to be
a key target of RNF168 and RNF8 in mediating cell proliferative
arrest and the genotoxic function of epirubicin. By contrast, there
were no signiﬁcant differences in cell proliferation rates and
epirubicin sensitivity in FOXM1-deﬁcient MEFs transfected with
vector control, RNF168 and RNF8. These results are in agreement
with the notion that RNF168 and RNF8 limit cell proliferation and
genotoxic drug resistance thorough promoting FOXM1 ubiquiti-
nation and stability (Figure 11).
Inverse correlation between RNF168 and FOXM1 expression in
breast cancer patient samples
To establish further the physiological and clinical relevance of the
negative regulation of FOXM1 expression by RNF168 in breast
cancer, FOXM1 and RNF168 expression was assessed by immu-
nohistochemistry in 116 breast cancer patient samples (Figure 12).
RNF168 was predominantly expressed in the nucleus, consistent
with its known function as a nuclear ubiquitin E3-ligase enzyme.
Immunohistochemical analysis results showed that RNF168
nuclear expression negatively and signiﬁcantly correlated with
FOXM1 expression (Pearson's correlation coefﬁcient: − 0.232,
P= 0.032; two-tailed). Consistently, most of the currently known
RNF168 functions appear to be restricted to the nucleus. However,
there were no signiﬁcant correlations between RNF168 and other
clinicopathological parameters, including PR (progesterone recep-
tor) status, histological type, lymph-node involvement and tumour
stage as well as patients’ survival. In line with our cell culture data,
there were no correlations between RNF8 and FOXM1 expression
in these breast cancer patient samples (Supplementary Figure S4),
which were obtained not related to any chemotherapy treatment.
DISCUSSION
FOXM1 has a key role in promoting DNA damage repair and
genotoxic agent resistance.5,8,9,15 Beside transcriptional control,
post-translational regulation has been shown to be another
important mode of control for FOXM1 expression, especially in
response to DNA damage.14,15 Previous reports have demon-
strated that RNF168 can modulate DDR by promoting protein
ubiquitination.11 In here, we show that RNF168 promotes K48-
linked ubiquitination of FOXM1 and targets it for degradation in
response to the anticancer DNA-damaging agent epirubicin. Using
a SUMOylation-defective mutant FOXM1 and the SUMOylation
inhibitor ginkgolic acid, we demonstrated that FOXM1 SUMOyla-
tion is required for recruiting RNF168 to FOXM1 to mediate its
ubiquitination and degradation. Paradoxically, RNF168 is a
ubiquitin (Ub) E3-ligase that possesses Ub-interacting motifs
domain but lacks SUMO-interacting motifs,24 and therefore, is
unlikely to recognize SUMOylated FOXM1 directly in response to
epirubicin. In agreement, we found that the recruitment of
RNF168 to FOXM1 requires the STUbL RNF8, and the association of
FOXM1 with RNF168 is lost in the absence of RNF8 in MCF-7 cells.
In a similar manner, RNF168 has also been shown to be recruited
to ubiquitinated chromatin proximal to damaged DNA in an RNF8-
dependent manner.24 Accordingly, RNF168 cannot initiate histone
H2A ubiquitination and is recruited only after RNF8-dependent
histone ubiquitination in DDR following DSBs.24 In line with this,
RNF8 is generally observed at DSBs before the recruitment of
RNF168.25 This cooperation between RNF8/RNF168 in DDR is well
documented. For example, RNF168/RNF8 has been shown to
mediate K63-linked ubiquitination of the histone H2A and variant
H2AX, ﬂanking the DSBs to coordinate DNA repair through
recruiting various signalling and repair factors, including BRCA1
Figure 9. RNF8 enhances the degradation of FOXM1 in epirubicin-treated MCF-7 cells. (a) MCF-7 cells were transfected with HA-RNF8 and Smart
Pool siRNA targeting RNF8 to study the effects of RNF8 overexpression and depletion, respectively, on FOXM1 expression. Representative
western blotting results showing that RNF8 overexpression and depletion only effectively decreases and increases FOXM1 expression in the
epirubicin-treated, but not in the untreated, MCF-7 cells. (b) MCF-7 cells transfected with control pcDNA3 or HA-RNF8 were treated with CHX, and
protein lysates prepared from 0 to 8 h following cyclohexamide treatment. Protein expression levels of FOXM1, RNF8 and β-tubulin in these
MCF-7 lysates were examined by western blotting. Densitometry was used to quantify the FOXM1 and β-tubulin levels from which independent
background readings were subtracted. Western blots are representative of three independent experiments. The relative expression levels shown
(right panels) are means± s.d. of the ratios of FOXM1 to β-tubulin levels relative to those at 0 h. (c) MCF-7 cells transfected with control NSC siRNA
or Smart Pool siRNA targeting RNF8 were treated with CHX, processed and analysed as in (b). (d) MCF-7 cells transfected with control pcDNA3 or
HA-RNF8 were treated with 1 μM epirubicin for 16 h. Protein lysates prepared from 0 to 8 h following cyclohexamide treatment were processed
and analysed as in (b). (e) MCF-7 cells transfected with control NSC siRNA or Smart Pool siRNA targeting RNF8 were treated with 1 μM epirubicin
for 16 h. Protein lysates prepared from 0 to 8 h following cyclohexamide treatment were processed and analysed as in (b). Statistical signiﬁcance
was determined by Student’s t--test (*P⩽ 0.05, **P⩽0.01, ***P⩽0.005; n.s., non-signiﬁcant).
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and 53BP1.26 Moreover, RNF168 also mediates K63-linked
ubiquitination of 53BP1 and controls its recruitment to DSBs in
DDR.27 These pair of E3-ligases have also been shown to function
together to enhance DNA repair at uncapped telomeres.28
Although the majority of the activities related to the RNF168/
RNF8 pathway involve K63-linked ubiquitination and protein
recruitment,26,27 we found that RNF8 and RNF168 cooperate to
primarily mediate the degradation-associated K48-linked ubiqui-
tination on FOXM1 in response to epirubicin. Consistent with our
results, the protein stability of 53BP1, like FOXM1, has also been
found to be regulated by RNF8/RNF168-mediated K48-linked
ubiquitination for efﬁcient DSB repair.22 However, except for
53BP1, few proteins have been identiﬁed to be substrates of
RNF8/RNF168-dependent K48-linked polyubiquitination.
The activity of ubiquitin E3-ligases is ﬁne-tuned by deubiqui-
tinating enzymes; of which, OTUB1 is one involved in DDR.29 We
have shown previously that OTUB1 can speciﬁcally limit FOXM1
polyubiquitination and its degradation, through its deubiquitinase
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Figure 10. RNF8 binds to FOXM1 and is required for the recruitment of RNF168 and the degradation of SUMOylated FOXM1. (a) MCF-7 cells
co-transfected with either the empty expression vectors, pcDNA3-HA and pcDNA3-Flag, or HA-RNF8 and Flag-FOXM1 were treated with
epirubicin (1 μM) for 0, 6 and 24 h. Co-immunoprecipitation (co-IP) was performed with an FOXM1 (αFOXM1) antibody on lysates from these
transfected MCF-7 cells pretreated with 10 μM MG132; Inputs (1/10 of IP) and IP products with αHA were resolved on western blot and probed
for Flag-FOXM1 and HA-RNF8 expression. The top band shows a likely post-translationally modiﬁed form of RNF8. The results showed that
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1 μM epirubicin for 0, 6 and 24 h. The cells were lysed and immunoprecipitated with IgG or an anti-RNF168 antibody. Inputs (1/10 of IP) and IP
products were analysed by western blotting and probed for RNF8, HA-FOXM1 and Flag-RNF168 expression. The result showed that RNF8 is
required for the recruitment of RNF168 to FOXM1.
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enzymatic activity.14 As a consequence, OTUB1 can antagonize
DNA damage-dependent ubiquitination action of RNF8/RNF168
on FOXM1.29 Alternatively, OTUB1 can speciﬁcally suppress
RNF168-dependent polyubiquitination independently of its cata-
lytic activity, through inhibiting UBC13 (also known as UBE2N), the
cognate E2 enzyme for RNF168.29 Intriguingly, OTUB1 preferen-
tially targets polyubiquitin chains joined by K48-bonds. The fact
that OTUB1 speciﬁcally targets FOXM1 also supports the fact that
FOXM1 is ubiquitinated by K48-linkage chains. It is notable that
although FOXM1 SUMOylation is required for the recruitment of
RNF8/RNF168 to mediate its degradation, it is possible that these
FOXM1 SUMOylation sites are also targets for RNF8/RNF168-
mediated ubiquitination, leading to the formation of mixed
SUMOylation/ubiquitination chains at these sites. Together, the
present and previous ﬁndings suggest that RNF8 and RNF168 can
be critical limiting factors in the control of FOXM1 expression,
particularly upon DNA damage and genotoxic agent treatment.
It is notable that depletion of RNF168 or RNF8 in WT MEFs
causes a signiﬁcant decrease in long-term cell proliferation and
clonal renewal in response to epirubicin, but neither RNF168 nor
RNF8 knockdown has any appreciable effects on clonogenicity in
FOXM1-deﬁcient MEFs. This suggests that both RNF168 and RNF8
target FOXM1 to restrict long-term clonal renewal and to
modulate genotoxic agent sensitivity. The high levels of RNF8
and low levels of RNF168 in steady-state untreated MCF-7 breast
cancer cells may also explain the inability of RNF8 overexpression
or its depletion to modulate FOXM1 expression. However, when
the endogenous RNF8 is downregulated and RNF168 upregulated
upon DNA damage, RNF8 becomes rate-limiting and can
cooperate with RNF168 to enhance FOXM1 ubiquitination and
degradation. The physiological relevance of the regulation of
FOXM1 by RNF168 is further underscored by the signiﬁcant
inverse correlation between FOXM1 and RNF168 in breast cancer
patient samples. The lack of correlations between FOXM1 and
RNF8 in clinical samples further supports our observations from
tissue culture model that RNF8 expression has little effect on
FOXM1 expression in samples not associated with any
chemotherapy.
Collectively, these results provide convincing evidence to
suggest that the ubiquitin E3-ligases RNF168 and RNF8 couple
SUMOylated FOXM1 to its ubiquitination and degradation in
response to the genotoxic agent epirubicin. In this way, RNF8 and
RNF168 integrate DNA-damage signalling with the transcriptional
network of FOXM1 to mediate DDR. These ﬁndings expand our
understanding on the mechanisms that regulate FOXM1 expres-
sion, and have important implications for cancer genotoxic agent
treatment and response.
MATERIALS AND METHODS
Cell culture, plasmids and transfection reagents
The MCF-7 cell line used originated from the American Type Culture
Collection and was acquired through CRUK cell bank (London, UK). MCF-7
cells and MEFs have previously been described.8,9 The eGFP-FOXM1 and
pcDNA3-FOXM1 WT and 5x(K4R) mutant expression plasmids have also
been described.15 The expression vectors for RNF8,25 RNF168,30 Flag-
RNF16831 and HA-RNF8 32 have also been described previously. The
pcDNA3-RNF4 plasmid was from Prof Ron T. Hay (University of Dundee,
Dundee, UK).33 The HA-ubiquitin, eGFP-FOXM1(WT) and eGFP-FOXM1-5x
(K4R) mutant plasmids have been described.15
Ni-NTA pull-down assays
His-tagged proteins were puriﬁed by nickel magnetic agarose beads
(Qiagen, Manchester, UK) under denaturing conditions as described.34 For
details, see also Supplementary Materials and Methods.
Luciferase reporter assay, gene silencing with siRNAs and measure
of FOXM1 protein turnover
Please see Supplementary Materials and Methods.
Western blotting, co-immunoprecipitation and antibodies
Western blotting was performed on whole-cell extracts by lysing cells in
buffer or precipitates in the presence of N-ethyl-amide (NEM) (10 mM)
(Sigma UK, Poole, UK) as previously described.9,35 See Supplementary
Materials and Methods for co-immunoprecipitation and antibodies used.
Clonogenic and sulphorhodamine-B assays
Clonogenic and sulphorhodamine-B (SRB) assays have been described.9
Also see Supplementary Methods and Materials for details.
Tissue microarray, immunohistochemistry and staining scoring
These reagents and analyses have been described.9 For details, see
Supplementary Methods and Materials.
Statistical analysis
All statistics were determined using SPSS 16.0 and Windows XP, Excel
(Imperial College London, Software Shop, UK). Also see Supplementary
Methods and Materials.
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Figure 11. Overexpression of RNF168 and RNF8 reduces clonogeni-
city in WT but not in Foxm1-deﬁcient MEFs. WT and Foxm1-deﬁcient
MEFs were transfected with the control pcDNA3, HA-RNF8 or Flag-
RNF168. Twenty-four hours after transfection, the 2000 cells were
seeded in six-well plates, treated with 0, 5 or 10 nM of epirubicn,
grown for 15 days and then stained with crystal violet (top panel).
The result (bottom panel) represents average of three independent
experiments± s.d. Statistical signiﬁcance was determined by
Student’s t-test (*P⩽0.05 , ***P⩽ 0.005; n.s., non-signiﬁcant).
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